Skip to main content
Premium Trial:

Request an Annual Quote

Xanthon Cuts Staff In Half as Venture Capital Remains Elusive

NEW YORK, April 15 - Xanthon has laid off approximately half its existing staff as it struggles to find private-equity financing, the company's COO and interim CEO, Neil Moore, told GenomeWeb.

 

The job cuts, made on April 9, brought the company's head count to 17 full-time employees and comes after 10 staffers were laid off in the fall.

"We continue to talk to funds, we think we have a good story, and we had to make some decisions to conserve the cash we had," Moore said.

The company's latest financing, announced in January, was a Small Business Innovation Research grant from the United States Army worth roughly $70,000. Cash from that grant was to help Xanthon study the feasibility of developing a portable electrochemical DNA biosensor.

Technology being developed by Research Triangle Park, NC-based Xanthon is built on an electrochemical platform that helps detect nucleic acids without the need for sample preparation, amplification, of the use of fluorescent, chemiluminescent, or radioactive labels.

 

A shortage of cash delayed the product's launch, which was scheduled for earlier in the year. A new launch date has not yet been set.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.